Xellsmart announces US IND clearances for iPSC-derived cell therapies for Parkinson’s disease and ALS
April 16, 2025
Xellsmart Biopharmaceutical (Suzhou) Co. Ltd. has announced IND clearances by the FDA for its XS-411 and XS-228 cell therapies, for Parkinson’s disease and amyotrophic lateral sclerosis (ALS), respectively.